This certification is a high recognition of the innovative strength of Nortion Medical! It fully demonstrates the clinical application value of this technology for the treatment of benign prostatic hyperplasia, and clarifies Nortion Medical's leading position in technological research and development.

Recently, Nortion Medical has received good news about its expansion overseas! After months of in-depth exchanges and technical verification, Nortion Medical officially signed a technical cooperation agreement with the medical team in Turkey, and simultaneously achieved the sales of the first batch of multiple devices and supporting consumables. This also marks the first time that this cutting-edge medical technology, independently developed in China, has been implemented overseas.

The 32nd Urological Academic Conference (CUA 2025), sponsored by the Chinese Medical Association and the Urology Branch of the Chinese Medical Association (CUA), organized by the Liaoning Medical Association and the Urology Branch of the Liaoning Medical Association, and co - organized by the Second Affiliated Hospital of Dalian Medical University, successfully concluded in Dalian.

The 5th Asia Summit on Global Health, organized by the Hong Kong Trade Development Council (HKTDC), commenced in Hong Kong on May 26. Under the theme "Partnering for a Resilient Future", the forum convened global ...

Recently, groundbreaking research on the NORTION® High-Frequency Irreversible Electroporation (H-FIRE) ablation system—developed independently by NORTION as a global leader in the field—was published in the Urology journal. The study not only validates the exceptional efficacy and safety of H-FIRE technology in treating Benign Prostatic Hyperplasia (BPH), but also provides robust scientific evidence for its clinical adoption."

Shanghai Nortion Medical Achieves Significant Breakthrough in Indonesia: Composite Steep Pulse Therapy Device and Disposable Ablation Electrode Needles Secure Import Medical Device Distribution License.

Following last month's achievement of the FDA Breakthrough Device Designation (BDD) for its independently developed Composite Steep Pulse Therapy Device, NORTION has now achieved major innovative breakthroughs on October 24!

NORTION's receipt of the FDA Breakthrough Device Designation (BDD) for its Composite Steep Pulse Therapy Device demonstrates the technology's cutting-edge innovation and exceptional clinical value. This achievement grants access to the U.S. innovation market...